Showing results (231-240 of 667) with videos related to

Sort By:
Pageof 67
Hemasphere|December 28, 2020
Association Between Peripheral Blood Cell Count Abnormalities and Health-Related Quality of Life in the General PopulationHanneke J C M Wouters, Isabelle A van Zeventer, Melanie M van der Klauw, et al.
Hemasphere|December 28, 2020
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3Christian Winther Eskelund, Kostas Dimopoulos, Arne Kolstad, et al.
Hemasphere|December 28, 2020
Recurrent NR3C1 Aberrations at First Diagnosis Relate to Steroid Resistance in Pediatric T-Cell Acute Lymphoblastic Leukemia PatientsJordy C G van der Zwet, Willem Smits, Jessica G C A M Buijs-Gladdines, et al.
Hemasphere|February 20, 2020
Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative NeoplasmsAndrew S Duncombe, Lesley A Anderson, Glen James, et al.
Hemasphere|February 20, 2020
Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma GroupStephen Daw, Dirk Hasenclever, Maurizio Mascarin, et al.
Hemasphere|February 20, 2020
Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIaChristoph Kannicht, Ilona Danßmann, Constanze Weilandt, et al.
Hemasphere|March 20, 2019
Increased Red Cell KCNN4 Activity in Sporadic Hereditary Xerocytosis Associated With Enhanced Single Channel Pressure Sensitivity of PIEZO1 Mutant V598MRadhakrishnan Gnanasambandam, Alicia Rivera, David H Vandorpe, et al.
Hemasphere|March 20, 2019
Controversies in the Treatment of Classical Hodgkin LymphomaDennis A Eichenauer, Marc André, Peter Johnson, et al.
Hemasphere|August 17, 2022
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular LymphomasHeike Horn, Vindi Jurinovic, Ellen Leich, et al.
Hemasphere|March 6, 2023
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related InjuryEnrica Federti, Alessandro Matte, Antonio Recchiuti, et al.
Pageof 67